RG6026

Phase 2

Roche

RG6026 is one of 426 therapeutic programs targeting Cerebral Amyloid Angiopathy. It is currently in Phase 2.

Indications

Total Trials

Active Trials

425

Competitors

Pipeline

Status by Indication[1]

Indication

Cerebral Amyloid AngiopathyActive, not recruiting

Frontotemporal DementiaActive, not recruiting

Heart Transplant RejectionActive, not recruiting

AgeActive, not recruiting

Alzheimer DiseaseActive, not recruiting

Kidney DiseaseActive, not recruiting

Gaucher Disease Type 1Active, not recruiting

Spinal Muscular Atrophy, Type 1Active, not recruiting

Fragile X SyndromeActive, not recruiting

Progressive Supranuclear PalsyActive, not recruiting

Cerebral Amyloid AngiopathyPhase 1

Active, not recruiting

Frontotemporal DementiaPhase 2

Active, not recruiting

Heart Transplant RejectionPhase 1

Active, not recruiting

AgePhase 2

Active, not recruiting

Alzheimer DiseasePhase 2

Active, not recruiting

Kidney DiseasePhase 1

Active, not recruiting

Gaucher Disease Type 1Phase 1

Active, not recruiting

Spinal Muscular Atrophy, Type 1Phase 1

Active, not recruiting

Fragile X SyndromePhase 1

Active, not recruiting

Progressive Supranuclear PalsyPhase 1

Active, not recruiting

Showing 10 of 23 indications

Competition

Competitive Landscape

460 competitors in Ulcerative Colitis

#DrugCompanyPhaseTrials

Omvoh

Eli Lilly

Phase 3

14 2

Velsipity

Pfizer

Phase 3

11 3

Jyseleca

Gilead

Phase 3

6 4

Skyrizi

AbbVie

Phase 3

6 5

Tremfya

Johnson & Johnson

Phase 3

2 6

Orencia

Bristol-Myers Squibb

Phase 3

1 7

Mounjaro

Eli Lilly

Phase 3

1 8

Adtralza

LEO Pharma

Phase 3

1 9

Purinethol

SStason

Phase 3

1 10

Deltavit

HHyundai Pharmaceutical Co., LTD.

Phase 3

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Sources

References

[1]
Open Targets Platform — Drug–disease associations for RG6026. EMBL-EBI & Wellcome Sanger Institute.
[2]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2
Company: Roche

RG6026

Status by Indication[1]

Competitive Landscape

References

Drug Info

Quick Facts

Related News